NasdaqGM - Nasdaq Real Time Price ? USD Conduit Pharmaceuticals Inc. (CDT) Follow Compare 0.1040 -0.0039 (-3.61%) At close: November 22 at 4:00 PM EST 0.1000 -0.00 (-3.85%) After hours: 7:59 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders Approval of composition of matter patent in key jurisdiction underscores the Company’s commitment to maximize future out-licensing valueNAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company’s lead asset, AZD1656, a Glucokinase Activator targ GlobeNewswire ? yesterday CDT -3.61% CDTTW Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound developme GlobeNewswire ? 3 days ago CDT -3.61% CDTTW Conduit Pharmaceuticals announces new addition to autoimmune pipeline Conduit Pharmaceuticals (CDT) announces the filing of two new patent applications relating to its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from AstraZeneca targeting a broad spectrum of autoimmune disorders. The patent applications include a novel composition of matter filing for CDT1656, the newly introduced asset in Conduit’s portfolio. CDT1656 combines AZD1656 with a second compound whose mechanism of action plays a critical role in the progression of autoimmune TipRanks ? 17 days ago CDT -3.61% CDTTW Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline Conduit Pharmaceuticals announces new addition to its autoimmune pipeline, underscored by composition of matter patent filing to strengthen its competitive position This new asset, CDT1656, combines AZD1656 with a second known-compound that has demonstrated immune-modulating effects across multiple autoimmune conditions, enhancing its therapeutic potentialThe addition of CDT1656 and the supporting composition of matter patent filing highlight Conduit’s commitment to building a robust asset portf GlobeNewswire ? 18 days ago CDT -3.61% CDTTW Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited (“Nirland”) and secured $1.2 million in new promissory notes through separate agreements with third parties. Conduit entered into a $2.65 million loan note with Nirland on A GlobeNewswire ? 21 days ago CDT -3.61% CDTTW Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024. Dr. David Tapolczay, Founder and CEO of Conduit, will give a virtual presentation available on-demand starting on September 9th at 7:00 am ET/12:00 pm BST. Dr. Tapolczay will also be available for in-person, one-on-one investor meet GlobeNewswire ? 2 months ago CDT -3.61% CDTTW Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656AZD1656, a HK-4 glucokinase activator initially developed by AstraZeneca for diabetes, is now being repurposed by Conduit for autoimmune disorders, leveraging its established safety profile and targeted immune-modulating effects SAN DIEGO and LONDON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: C GlobeNewswire ? 3 months ago CDT -3.61% CDTTW Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor AZD5904 targeting idiopathic male infertilityAssets have shown favorable preclinical and Phase I data. Conduit to initiate Phase II clinical trials SAN DIEGO and LONDON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”), today announced that the Co GlobeNewswire ? 3 months ago CDT -3.61% CDTTW Conduit Pharmaceuticals Granted Patent Approval For Autoimmune Diseases Treatment By Karen Roman Conduit Pharmaceuticals Inc. (Nasdaq: CDT) said IP Australia approved a patent application for an activator targeting autoimmune diseases. This should open the path to approvals in other countries, Conduit said in a statement. “With up to 20 years of patent protection and drug substance classification secured, this patent not only validates the […] Exec Edge ? 4 months ago CDT -3.61% CDTTW Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases Composition of matter patent approval underscores the Company’s solid-form technology to maximize future value and ability to strengthen and broaden its intellectual property portfolioSAN DIEGO and LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the approval of a composition of matter patent application by IP Australia, achieving successful examination of a patent on its lead asset, an GlobeNewswire ? 4 months ago CDT -3.61% CDTTW Conduit Pharmaceuticals to Join Russell 3000? Index SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (the “Company” or “Conduit"), today announced the Company is set to join the broad-market Russell 3000? Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures th GlobeNewswire ? 5 months ago CDT -3.61% CDTTW A Presidio Property Trust Major Investment To Be Part of Russell 2000? SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ: SQFT; SQFTP; SQFTW) (“Presidio” or the “Company”), an internally managed, diversified real estate investment trust (“REIT”), has announced that Conduit Pharmaceuticals Inc. (NASDAQ: CDT, CDTTW) (“Conduit”), of which the Company owns approximately 6.3%, is expected to be added to the Russell 2000 Index effective at the open of US equity markets on Monday, July 1, 2024, as part of the annual reconstitution of the Ru GlobeNewswire ? 5 months ago SQFT SQFTW CDT -3.61% Conduit Pharmaceuticals Adds Key Leadership Positions By Daniella Parra Conduit Pharmaceuticals Inc. (Nasdaq: CDT) announced the appointment of Dr. Joanne Holland as Chief Scientific Officer and Dr. Jeff Lindeman as a Consultant on intellectual property strategies. The company said Dr. Holland brings over 20 years of experience in drug development, with expertise in solid-form technology and Dr. Lindeman, an experienced IP […] Exec Edge ? 8 months ago CDT -3.61% CDTTW Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit’s commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the appointment of Dr. Joanne Holland as Chief Scienti GlobeNewswire ? 8 months ago CDT -3.61% CDTTW Conduit Pharmaceuticals Opens New Laboratory in UK By Karen Roman Conduit Pharmaceuticals Inc. (Nasdaq: CDT), a clinical-stage life science company, reported it has opened a new cutting-edge laboratory space in Cambridge, U.K. This new facility sits within a space of 150 acres and 2 million square feet of advanced technology and laboratory buildings and it houses some of the world’s top technology […] Exec Edge ? 8 months ago CDT -3.61% CDTTW Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation. This strategic acquisition marks a pivotal milestone for Conduit, positioning the Company for portfolio expansion, enhanced development capabilities, and growth of GlobeNewswire ? 8 months ago CDT -3.61% CDTTW Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit"), a multi-asset, clinical-stage life science company delivering an efficient model for compound development, today announced CEO Dr. David Tapolczay, will be participating in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, being held February 13-14, 2024. Dr. Tapolczay is scheduled to present on Wednesday, February 14, 2024, at 8:00 am EST/13:30 GMT, and will be particip GlobeNewswire ? 9 months ago CDT -3.61% CDTTW Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return CDT S&P 500 YTD -97.71% +25.15% 1-Year -92.00% +31.54% 3-Year -98.95% +30.46%
